A provision in the current appropriations bill would create a Medicare coverage pathway for FDA‑approved multi‑cancer early detection (MCED) tests, with reimbursement modeled on the multi‑target stool DNA colorectal test and payments beginning in 2029. The measure would allow phased eligibility for ages 50–65, expanding year by year. The amendment addresses a long‑standing industry priority to decouple MCED reimbursement from USPSTF endorsement, potentially reshaping commercial models for companies developing blood‑based cancer screens. Analysts warn the impact will vary by company depending on existing reimbursement strategies and code structures; stakeholders expect legislative language and implementation details to determine real‑world uptake.